News
Press Releases
Press Release Archive
|
|
|
Please Note: Press Releases are in Adobe .pdf
format.
To view these documents requires the use
of Adobe
Acrobat Reader, available for free.
2003
Court Rules in Favor of NaPro in Mylan Patent Infringement Case
December 23, 2003
NaPro BioTherapeutics Announces the Appointment of Anne Bailey as Vice President and General Manager, Genomics Division
December 22, 2003
NaPro Completes Sale of Worldwide Paclitaxel Business to Mayne Pharma
December 12, 2003
NaPro Awarded Phase I SBIR Grant for Research On Muscular Dystrophy
December 4, 2003
NaPro Unveils Targeted Therapeutic Platform For Lung, Breast, And Other Cancers At AACR-NCI-EORTC Conference
November 19, 2003
NaPro Reports Third Quarter 2003 Results
November 13, 2003
December 1 Trial Date Set in NaPro vs Mylan Patent Infringement Case
November 12, 2003
NaPro BioTherapeutics to Present at The Wall Street Analyst Forum on November 10
November 7, 2003
NaPro Announces Favorable Federal Court Ruling Against Mylan
October 6, 2003
NaPro Launches New Corporate Website
October 6, 2003
NaPro Gene Editing Technology Reviewed in Nature Reviews Genetics and Journal Of Clinical Investigation
September 16, 2003
NaPro to Sell Worldwide Generic Paclitaxel Business to Mayne Group Limited
August 26, 2003
NaPro Reports Second Quarter 2003 Results
August 7, 2003
NaPro Collaborates with Leading Agricultural Research Institution to Improve Wheat
July 23, 2003
NaPro Advances Its Sickle Cell Program With Two Research Collaborations
June 24, 2003
NaPro BioTherapeutics Regains Compliance with Nasdaq Small Cap Market Bid Price Requirements
June 16, 2003
NaPro's Technology Extends Life of Neuronal Cells by up to 40% in Huntington's Disease Model
June 8, 2003
NaPro's Gene Editing Demonstrates Gene Alteration in Human Cells
June 6, 2003
NaPro BioTherapeutics Announces Improved First Quarter 2003 Financial Results
May 15, 2003
NaPro to Sell Worldwide Paclitaxel Business
April 9, 2003
NaPro BioTherapeutics Announces Sale of Technical and Analytical Services Group to ChromaDex
April 9, 2003
NaPro BioTherapeutics Licenses Peptide Targeting Technology from The University of Texas M. D. Anderson Cancer Center
March 26, 2003
NaPro Gene Editing Technology Highlighted in Three Scientific Journals
March 6, 2003
NaPro BioTherapeutics Reports Strong Fourth Quarter and Full-year 2002 Results
February 25, 2003
NaPro Applies for Transfer of Common Stock Listing to Nasdaq SmallCap Market
February 12, 2003
NaPro Acquires Pangene's Gene Isolation Business
January 27, 2003
George M. Gould Joins NaPro Board of Directors
January 23, 2003
2002
NaPro BioTherapeutics Reports Third Quarter Operations
November 7, 2002
NaPro BioTherapeutics to Report Third Quarter Financial Results on November 7, 2002
November 6, 2002
NaPro BioTherapeutics to Present at Salomon Smith Barney 2002 Global Health Care Conference
October 24, 2002
NaPro Introduces New Pharmacogenomic Service at ASHG Annual Meeting
October 11, 2002
Jeffrey White Appointed President, Genomics Division, NaPro BioTherapeutics
October 8, 2002
NaPro BioTherapeutics to Present at Wells Fargo Securities 'Class of 2002' Conference
September 3, 2002
NaPro BioTherapeutics Reports Profitable Second Quarter
July 16, 2002
NaPro to Report Second Quarter Financial Results
July 15, 2002
European Patent Office Opposition Division Revokes NaPro's Paclitaxel Formulation Patent
July 3, 2002
NaPro BioTherapeutics to Present at the UBS Warburg Global Specialty Pharmaceuticals Conference
June 4, 2002
NaPro Receives $8 Million Milestone Payment
May 20, 2002
NaPro BioTherapeutics Announces First Quarter Financial Results
May 14, 2002
NaPro Announces Webcast of FDA Approval Conference Call for May 9, 2002
May 8, 2002
Abbott Laboratories and NaPro BioTherapeutics Receive FDA Approval for Generic Paclitaxel
May 8, 2002
NaPro BioTherapeutics Announces Fourth Quarter and Year End Financial Results
April 1, 2002
NaPro Announces $16 Million Private Placement of Securities
February 14, 2002
NaPro BioTherapeutics Provides Update on ANDA Filing With FDA
January 10, 2002
2001
NaPro BioTherapeutics to Webcast Analyst Briefing on Agreement with Bristol-Myers Squibb
November 29, 2001
NaPro BioTherapeutics and Abbott Laboratories Enter into Paclitaxel Cross-License Agreement With Bristol-Myers Squibb
November 29, 2001
NaPro BioTherapeutics Invites You To Join Its Company Presentation at the Robertson Stephens Medical Conference on the Web
November 28, 2001
NaPro Comments on Court of Appeals Action
November 7, 2001
NaPro Receives New Paclitaxel Formulation Patent
October 23, 2001
NaPro BioTherapeutics to Present at the UBS Warburg Global Life Sciences Conference
October 9, 2001
NaPro Forms Scientific Advisory Board for Genomics Division
September 18, 2001
NaPro BioTherapeutics Licenses Patents Relating to Peptide-Targeted Taxane Delivery
September 10, 2001
NaPro BioTherapeutics Announces Second Quarter Financial Results
August 14, 2001
NaPro Licenses Paclitaxel in Japan to JCR Pharmaceuticals
June 21, 2001
NaPro BioTherapeutics to Present at the UBS Warburg 5th Annual Global Specialty Pharmaceuticals Conference
May 17, 2001
NaPro BioTherapeutics Announces First Quarter Financial Results
May 16, 2001
NaPro BioTherapeutics Receives $5 Million Milestone
April 24, 2001
Abbott Laboratories and NaPro BioTherapeutics File Paclitaxel ANDA
March 6, 2001
NaPro Signs Paclitaxel Agreement for Europe
March 5, 2001
NaPro Paclitaxel Approved in Israel
January 8, 2001
2000
NaPro Licenses Gene Altering Technology and Forms Genomics Division
November 30, 2000
NaPro BioTherapeutics Completes $17.5 Million Private Placement
November 17, 2000
NaPro BioTherapeutics Announces Third Quarter Financial Results
November 9, 2000
NaPro Receives New Paclitaxel Formulation Patent and NaPro Amends lawsuit against Bristol-Myers Squibb to include newly issued patent
October 31, 2000
NaPro BioTherapeutics Files Patent Infringement Suit Relating to Taxol Against Bristol-Myers Squibb Corporation
September 18, 2000
NaPro BioTherapeutics Announces Second Quarter Financial Results
August 11, 2000
NaPro Adds Three New Board Members
July 21, 2000
NaPro Receives $4 Million Milestone and Expands Its Strategic Paclitaxel Relationship with Abbott Laboratories
June 28, 2000
NaPro Appoints Marc Ostro to its Board of Directors
June 14, 2000
NaPro Licenses Faulding for Paclitaxel in Latin America, South Africa and other countries
June 8, 2000
NaPro BioTherapeutics Announces First Quarter Financial Results
May 11, 2000
NaPro BioTherapeutics Ends Licensing Negotiation
April 14, 2000
NaPro BioTherapeutics Announces Fourth Quarter and Year End Financial Results
March 15, 2000
1999
NaPro BioTherapeutics Announces Third Quarter Financial Results
November 11, 1999
NaPro BioTherapeutics Announces Second Quarter Financial Results
August 14, 1999
NaPro to Redeem The Majority of Its Convertible Securities Following New Financing
July 26, 1999
Abbott and NaPro BioTherapeutics Sign Development Agreement for Cancer Compound Paclitaxel
July 26, 1999
NaPro Amends Terms of Convertible Preferred Stocks
June 23, 1999
NaPro BioTherapeutics Announces First Quarter Financial Results
May 17, 1999
1998
NaPro BioTherapeutics Announces Third Quarter Financial Results
November 11, 1998
NaPro Announces New Board Appointments
November 4, 1998
NaPro BioTherapeutics Prevails In Administration Patent Suit Against Bristol-Myers Squibb
August 25, 1998
NaPro BioTherapeutics Announces Second Quarter Financial Results
August 11, 1998
NaPro Receives Paclitaxel Formulation Patent In Europe
August 5, 1998
NaPro Partner F.H. Faulding Defeats Bristol-Myers In Australian Courts
July 24, 1998
NaPro BioTherapeutics Announce First Quarter Results
April 9, 1998
NaPro BioTherapeutics Receives US Patent for Paclitaxel
March 23, 1998
Ivax and NaPro Terminate Paclitaxel Development and Marketing Agreement
March 23, 1998
NaPro BioTherapeutics Announces Fourth Quarter and Year End Results
March 17, 1998
NaPro BioTherapeutics Announces Paclitaxel, Anzatax, Approved In Singapore
March 12, 1998
NaPro Restructures Outstanding Convertible Securities
January 8, 1998
1997
NaPro BioTherapeutics Announces Private Placement of $5 Million Senior Convertible Preferred Stock
December 9, 1997
NaPro BioTherapeutics, Inc. Announces FDA Advisory Panel Recommendation for Approval of Anti-Cancer Drug Paxene
September 19, 1997
NaPro BioTherapeutics Announces Second Quarter Financial Results
August 12, 1997
Ivax Corporation and NaPro BioTherapeutics Announce Submission of New Drug Application for Paclitaxel
April 1, 1997
NaPro BioTherapeutics Announces Fourth Quarter and Year End Financial Results
February 11, 1997
|
|
|
